CN112138138B - Pharmaceutical composition for treating gout and preparation method thereof - Google Patents
Pharmaceutical composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN112138138B CN112138138B CN202011300901.4A CN202011300901A CN112138138B CN 112138138 B CN112138138 B CN 112138138B CN 202011300901 A CN202011300901 A CN 202011300901A CN 112138138 B CN112138138 B CN 112138138B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- gout
- alanine
- methionine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 38
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 36
- 229930013930 alkaloid Natural products 0.000 claims abstract description 21
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 20
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 19
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 19
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 19
- 229960003767 alanine Drugs 0.000 claims abstract description 19
- 229960004452 methionine Drugs 0.000 claims abstract description 19
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 19
- 239000011718 vitamin C Substances 0.000 claims abstract description 19
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 18
- 229930064664 L-arginine Natural products 0.000 claims abstract description 18
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 18
- 235000019454 L-leucine Nutrition 0.000 claims abstract description 18
- 239000004395 L-leucine Substances 0.000 claims abstract description 18
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960003136 leucine Drugs 0.000 claims abstract description 18
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 18
- 239000011591 potassium Substances 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 150000003384 small molecules Chemical class 0.000 claims abstract description 18
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims abstract description 17
- 241000251468 Actinopterygii Species 0.000 claims abstract description 17
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241000195620 Euglena Species 0.000 claims abstract description 17
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 17
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930195722 L-methionine Natural products 0.000 claims abstract description 17
- 229940014041 hyaluronate Drugs 0.000 claims abstract description 17
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 16
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 16
- -1 D-glucosamine ketoglutarate Chemical compound 0.000 claims abstract description 12
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 17
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 17
- 229940116269 uric acid Drugs 0.000 abstract description 17
- 206010003246 arthritis Diseases 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 208000006820 Arthralgia Diseases 0.000 abstract description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 235000019766 L-Lysine Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000037039 Monarthritis Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 201000001509 acute urate nephropathy Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 208000016839 purine metabolism disease Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000026101 uric acid urolithiasis Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种痛风治疗药物及其制备方法，尤其是涉及一种用于治疗痛风的药物组合物及其制备方法。The invention relates to a drug for treating gout and a preparation method thereof, in particular to a pharmaceutical composition for treating gout and a preparation method thereof.
背景技术Background technique
痛风是嘌呤代谢障碍所致的一组异质性慢性代谢性疾病， 其临床特点为高尿酸血症、反复发作的痛风性急性关节炎、间质性肾炎和痛风石形成；严重者伴关节畸形或尿酸性尿路结石。痛风临床特点为：高尿酸血症；痛风性急性关节炎反复发作；痛风石形成和沉积痛风石性漫性关节炎；关节畸形等。Gout is a group of heterogeneous chronic metabolic diseases caused by purine metabolism disorders, and its clinical features are hyperuricemia, recurrent gouty acute arthritis, interstitial nephritis and tophi formation; severe cases are accompanied by joint deformities or uric acid urolithiasis. The clinical features of gout are: hyperuricemia; recurrent gouty acute arthritis; tophi formation and deposition of tophi chronic arthritis; joint deformity, etc.
通风形成过程主要是尿酸过度积累造成，尿酸的积聚主要原因有：过量食用高嘌呤的食物，体内嘌呤代谢出现问题，排泄量过少，尿酸无法正常排泄。根据尿酸产生的机理，要防治好痛风必需减少尿酸的产生，要减少尿酸的产生必需减少体内的嘌呤，减少体内的嘌呤必需减少核酸的氧化分解，和嘌呤的摄入，同时加强尿酸的排除。目前，市场上治疗痛风的药物较多，有秋水仙碱、葵花盘生物碱、别嘌呤醇、丙磺舒等药物，这些药物治标不治本，并造成造成肝肾功能严重伤害、溶血性贫血、过敏性休克等一系列副作用，一些植物碱可以中和尿酸，但患者出现疼痛加剧的现象。The formation of ventilation is mainly caused by the excessive accumulation of uric acid. The main reasons for the accumulation of uric acid are: excessive consumption of high-purine foods, problems with purine metabolism in the body, too little excretion, and uric acid cannot be excreted normally. According to the mechanism of uric acid production, to prevent and treat gout well, it is necessary to reduce the production of uric acid. To reduce the production of uric acid, it is necessary to reduce the purines in the body. To reduce the purines in the body, it is necessary to reduce the oxidative decomposition of nucleic acids and the intake of purines, while strengthening the elimination of uric acid. At present, there are many drugs for the treatment of gout on the market, including colchicine, sunflower alkaloids, allopurinol, probenecid and other drugs. A series of side effects such as anaphylactic shock, some plant alkaloids can neutralize uric acid, but patients experience increased pain.
发明内容Contents of the invention
本发明所要解决的技术问题在于提供一种用于治疗痛风的药物组合物。The technical problem to be solved by the present invention is to provide a pharmaceutical composition for treating gout.
本发明所要解决的另一技术问题在于提供上述用于治疗痛风的药物组合物的制备方法。Another technical problem to be solved by the present invention is to provide a preparation method of the above-mentioned pharmaceutical composition for treating gout.
本发明采用的技术方案是：The technical scheme adopted in the present invention is:
一种用于治疗痛风的药物组合物，功效成分由裸藻β-1,3-葡聚糖、复合活性生物碱、深海鱼肽、小分子透明质酸钾（分子量小于3000）、D-氨基葡萄糖酮戊二酸盐、谷氨酰胺、L-丙氨酸、L-精氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和维生素C组成，按其重量份数计裸藻β-1,3-葡聚糖18-30份、复合活性生物碱15-35份、深海鱼肽3-15份、小分子透明质酸钾（分子量小于3000）2-5份、D-氨基葡萄糖酮戊二酸盐 5-10份、谷氨酰胺3-5份、L-丙氨酸2-5份、L-精氨酸3-6份、L-蛋氨酸2-5份、L-赖氨酸3-6份、L-亮氨酸5-9份、维生素C 0.2-1份。A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, in parts by weight naked 18-30 parts of algal β-1,3-glucan, 15-35 parts of complex active alkaloids, 3-15 parts of deep-sea fish peptides, 2-5 parts of small molecule potassium hyaluronate (molecular weight less than 3000), D- Glucosamine ketoglutarate 5-10 parts, glutamine 3-5 parts, L-alanine 2-5 parts, L-arginine 3-6 parts, L-methionine 2-5 parts, L- 3-6 parts of lysine, 5-9 parts of L-leucine, 0.2-1 part of vitamin C.
优选的，上述用于治疗痛风的药物组合物，按其重量份数计裸藻β-1,3-葡聚糖26.5份、复合活性生物碱29.4份、深海鱼肽7.2份、小分子透明质酸钾3.5份、D-氨基葡萄糖酮戊二酸盐 8.6份、谷氨酰胺4.1份、L-丙氨酸3.0份、L-精氨酸4.2份、L-蛋氨酸3.5份、L-赖氨酸3.5份、L-亮氨酸6.0份、维生素C 0.5份。Preferably, the above-mentioned pharmaceutical composition for treating gout comprises 26.5 parts by weight of euglena β-1,3-glucan, 29.4 parts of complex active alkaloids, 7.2 parts of deep-sea fish peptide, small molecule hyaluronic acid 3.5 parts of potassium phosphate, 8.6 parts of D-glucosamine ketoglutarate, 4.1 parts of glutamine, 3.0 parts of L-alanine, 4.2 parts of L-arginine, 3.5 parts of L-methionine, L-lysine 3.5 parts, L-leucine 6.0 parts, vitamin C 0.5 parts.
上述用于治疗痛风的药物组合物可以制作为散剂、胶囊剂或颗粒剂。The above-mentioned pharmaceutical composition for treating gout can be made into powder, capsule or granule.
上述用于治疗痛风的药物组合物的制备方法，具体步骤如下：The preparation method of the above-mentioned pharmaceutical composition for the treatment of gout, the specific steps are as follows:
（1）按重量份数称取裸藻β-1,3-葡聚糖、复合活性生物碱、深海鱼肽、小分子透明质酸钾（分子量小于3000）、D-氨基葡萄糖酮戊二酸盐、谷氨酰胺、L-丙氨酸、L-精氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和维生素C；(1) Weigh euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-glucosamine ketoglutarate in parts by weight Salt, Glutamine, L-Alanine, L-Arginine, L-Methionine, L-Lysine, L-Leucine and Vitamin C;
（2）将步骤（1）中各组分混合均匀即得。(2) Mix all components in step (1) evenly.
本发明的有益效果是：The beneficial effects of the present invention are:
所述用于治疗痛风的药物组合物，可有效改善和治疗痛风等代谢性关节炎、风湿性关节炎、类风湿性关节炎等慢性疾病，修复关节，减少关节疼痛，增加肌肉合成，加快尿酸代谢。The pharmaceutical composition for treating gout can effectively improve and treat metabolic arthritis such as gout, rheumatoid arthritis, rheumatoid arthritis and other chronic diseases, repair joints, reduce joint pain, increase muscle synthesis, and accelerate uric acid metabolism.
具体实施方式Detailed ways
为进一步说明本发明，结合以下实施例具体说明：For further illustrating the present invention, specifically illustrate in conjunction with following examples:
实施例1Example 1
一种用于治疗痛风的药物组合物，功效成分由裸藻β-1,3-葡聚糖、复合活性生物碱、深海鱼肽、小分子透明质酸钾（分子量小于3000）、D-氨基葡萄糖酮戊二酸盐、谷氨酰胺、L-丙氨酸、L-精氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和维生素C组成，其中，裸藻β-1,3-葡聚糖26.5%、复合活性生物碱29.4%、深海鱼肽7.2%、小分子透明质酸钾3.5%、D-氨基葡萄糖酮戊二酸盐 8.6%、谷氨酰胺4.1%、L-丙氨酸3.0%、L-精氨酸4.2%、L-蛋氨酸3.5%、L-赖氨酸3.5%、L-亮氨酸6.0%、维生素C 0.5%。A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which Euglena β-1 ,3-glucan 26.5%, compound active alkaloid 29.4%, deep-sea fish peptide 7.2%, small molecule potassium hyaluronate 3.5%, D-glucosamine ketone glutarate 8.6%, glutamine 4.1%, L -Alanine 3.0%, L-Arginine 4.2%, L-Methionine 3.5%, L-Lysine 3.5%, L-Leucine 6.0%, Vitamin C 0.5%.
上述用于治疗痛风的药物组合物制作为散剂（5g/袋），制备方法具体步骤如下：The above-mentioned pharmaceutical composition for treating gout is made into a powder (5g/bag), and the specific steps of the preparation method are as follows:
（1）按重量份数称取裸藻β-1,3-葡聚糖、复合活性生物碱、深海鱼肽、小分子透明质酸钾（分子量小于3000）、D-氨基葡萄糖酮戊二酸盐、谷氨酰胺、L-丙氨酸、L-精氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和维生素C；(1) Weigh euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-glucosamine ketoglutarate in parts by weight Salt, Glutamine, L-Alanine, L-Arginine, L-Methionine, L-Lysine, L-Leucine and Vitamin C;
（2）将步骤（1）中各组分混合均匀即得。(2) Mix all components in step (1) evenly.
实施例2Example 2
一种用于治疗痛风的药物组合物，功效成分由裸藻β-1,3-葡聚糖、复合活性生物碱、深海鱼肽、小分子透明质酸钾（分子量小于3000）、D-氨基葡萄糖酮戊二酸盐、谷氨酰胺、L-丙氨酸、L-精氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和维生素C组成，其中，裸藻β-1,3-葡聚糖30%、复合活性生物碱15%、深海鱼肽15%、小分子透明质酸钾（分子量小于3000）5%、D-氨基葡萄糖酮戊二酸盐 5%、谷氨酰胺5%、L-丙氨酸5%、L-精氨酸3%、L-蛋氨酸2%、L-赖氨酸3%、L-亮氨酸9%、维生素C 1%。A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which Euglena β-1 , 30% 3-glucan, 15% complex active alkaloids, 15% deep-sea fish peptide, 5% small molecule potassium hyaluronate (molecular weight less than 3000), 5% D-glucosamine ketoglutarate, glutamine Amide 5%, L-alanine 5%, L-arginine 3%, L-methionine 2%, L-lysine 3%, L-leucine 9%, vitamin C 1%.
制备方法参照实施例1。The preparation method refers to Example 1.
实施例3Example 3
一种用于治疗痛风的药物组合物，功效成分由裸藻β-1,3-葡聚糖、复合活性生物碱、深海鱼肽、小分子透明质酸钾（分子量小于3000）、D-氨基葡萄糖酮戊二酸盐、谷氨酰胺、L-丙氨酸、L-精氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和维生素C组成，其中，裸藻β-1,3-葡聚糖18%、复合活性生物碱35%、深海鱼肽3%、小分子透明质酸钾（分子量小于3000）2%、D-氨基葡萄糖酮戊二酸盐10%、谷氨酰胺3%、L-丙氨酸2%、L-精氨酸6%、L-蛋氨酸5%、L-赖氨酸6%、L-亮氨酸5%、维生素C 0.2%。A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which Euglena β-1 ,3-glucan 18%, complex active alkaloid 35%, deep-sea fish peptide 3%, small molecule potassium hyaluronate (molecular weight less than 3000) 2%, D-glucosamine ketoglutarate 10%, glutamine Amide 3%, L-alanine 2%, L-arginine 6%, L-methionine 5%, L-lysine 6%, L-leucine 5%, vitamin C 0.2%.
制备方法参照实施例1。The preparation method refers to Example 1.
实施例4Example 4
一种用于治疗痛风的药物组合物，功效成分由裸藻β-1,3-葡聚糖、复合活性生物碱、深海鱼肽、小分子透明质酸钾（分子量小于3000）、D-氨基葡萄糖酮戊二酸盐、谷氨酰胺、L-丙氨酸、L-精氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和维生素C组成，其中，裸藻β-1,3-葡聚糖23%、复合活性生物碱27%、深海鱼肽10%、小分子透明质酸钾（分子量小于3000）4%、D-氨基葡萄糖酮戊二酸盐8%、谷氨酰胺4%、L-丙氨酸3%、L-精氨酸5%、L-蛋氨酸4%、L-赖氨酸4%、L-亮氨酸7%、维生素C 0.6%。A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which Euglena β-1 , 23% 3-glucan, 27% complex active alkaloids, 10% deep-sea fish peptide, 4% small molecule potassium hyaluronate (molecular weight less than 3000), 8% D-glucosamine ketoglutarate, glutamine Amide 4%, L-alanine 3%, L-arginine 5%, L-methionine 4%, L-lysine 4%, L-leucine 7%, vitamin C 0.6%.
制备方法参照实施例1。The preparation method refers to Example 1.
组方分析：Team analysis:
（1）治标治本，裸藻葡聚糖可降低尿酸、降低胆固醇、增强抵抗力，复合活性生物碱直接中和尿酸，谷氨酰胺、丙氨酸、精氨酸（扩张血管）、VC具有协同护肝养肾的作用；从养肝养肾的根本上治疗通风；(1) Treat the symptoms and cure the root cause. Euglenoglucan can reduce uric acid, lower cholesterol, and enhance resistance. The compound active alkaloids can directly neutralize uric acid. Glutamine, alanine, arginine (vasodilation), and VC have synergistic effects The function of protecting the liver and nourishing the kidney; treating ventilation from the root of nourishing the liver and nourishing the kidney;
（2）小分子纳米物质，快速吸收，无毒副作用，没有任何激素，没有依赖性；(2) Small molecular nano-materials, fast absorption, no toxic side effects, no hormones, no dependence;
（3）赖氨酸、丙氨酸具有协同利尿的作用，有利于尿酸的排出，与蛋氨酸协同抑制重症高血压病（一般通风伴有高血压）；(3) Lysine and alanine have a synergistic diuretic effect, which is beneficial to the excretion of uric acid, and cooperate with methionine to inhibit severe hypertension (generally ventilated with high blood pressure);
（4）小分子透明质酸钾和D-氨基葡萄糖酮戊二酸盐具有协同保护关节、软化关节、软化血管等作用，减少关节疼痛，修复关节；(4) Potassium hyaluronate and D-glucosamine glutarate have synergistic effects of protecting joints, softening joints, softening blood vessels, etc., reducing joint pain and repairing joints;
（5）维生素C，消炎止痛，修复肾脏，减少体内尿素含量，促进其它四种成分的吸收。(5) Vitamin C, anti-inflammatory and pain-relieving, repairs the kidneys, reduces urea content in the body, and promotes the absorption of the other four ingredients.
各组分协同作用，治疗痛风效果显著。Each component acts synergistically, and the effect of treating gout is remarkable.
实验例1Experimental example 1
应用实施例1所述药物组合物（5g/袋），服用方法为每天4次，每6小时服用一次，每次饮水500-700ML纯净水。服用30天后为一个疗程。试验痛风患者50例，其中中青年30例，青年患者年龄为20-45岁，平均年龄35.5岁，中老年患者为46-76岁，平均年龄为57.2岁。患者均为男性，所有患者均符合痛风的诊断标准。青年患者尿酸水平平均为523±71.2μmol /L，中老年患者尿酸水平平均为 565±62.3μmol / L。临床发作次数青年患者平均3.5±0.6次/年，中老年患者平均3.8±0.4次/年。Apply the pharmaceutical composition (5g/bag) described in Example 1, and take it 4 times a day, once every 6 hours, and drink 500-700ML of purified water each time. A course of treatment is taken after 30 days. 50 gout patients were tested, including 30 young and middle-aged patients. The young patients were 20-45 years old, with an average age of 35.5 years, and the middle-aged and elderly patients were 46-76 years old, with an average age of 57.2 years. All patients were male, and all patients met the diagnostic criteria for gout. The average uric acid level in young patients was 523±71.2 μmol/L, and the average uric acid level in middle-aged and elderly patients was 565±62.3 μmol/L. The average number of clinical attacks was 3.5±0.6 times/year for young patients, and 3.8±0.4 times/year for middle-aged and elderly patients.
本组收治的痛风患者50例患者，主要病变，单一关节炎23例，多关节炎34 例，主要受累关节为第一趾关节46例，踝关节16例，其它趾跖关节11例，膝关节9例。经实施例1药物治疗42例完全缓解, 7例好转，临床有效率达98.0％。There were 50 patients with gout treated in this group. The main lesions were 23 cases of monoarthritis and 34 cases of polyarthritis. The main affected joints were 46 cases of the first toe joint, 16 cases of ankle joint, 11 cases of other toe-metatarsal joints, and knee joints. 9 cases. After the drug treatment of Example 1, 42 cases were completely relieved, 7 cases took a turn for the better, and the clinical effective rate reached 98.0%.
实验例2Experimental example 2
选取一组8位患者，患者年龄在43-61岁，全部为男性，进行跟踪测试，8位患者静脉血测得尿酸值均大于550umol/L，服用应用实施例1所述药物组合物（5g/袋）、4次/天，每6小时服用一次，每次饮水500-700ML纯净水。通过观察，在第5天检测尿酸含量下降较快，在30天检测时6位患者恢复正常值，通过60天治疗，全部恢复正常。A group of 8 patients were selected, the patients were 43-61 years old, all of them were men, and a follow-up test was carried out. The uric acid values measured in the venous blood of 8 patients were all greater than 550umol/L, and they took the pharmaceutical composition described in Application Example 1 (5g /bag), 4 times/day, take it every 6 hours, and drink 500-700ML of purified water each time. Through observation, the uric acid content decreased rapidly on the 5th day, and the 6 patients returned to normal values at the 30-day test, and all returned to normal after 60 days of treatment.
以上所述实施例仅仅是对本发明的优选实施方式进行描述，并非对本发明的范围进行限定，在不脱离本发明设计精神的前提下，本领域普通工程技术人员对本发明的技术方案作出的各种变形和改进，均应落入本发明的权利要求书确定的保护范围内。The above-mentioned embodiments are only descriptions of the preferred implementation modes of the present invention, and are not intended to limit the scope of the present invention. Variations and improvements should fall within the scope of protection defined by the claims of the present invention.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011300901.4A CN112138138B (en) | 2020-11-19 | 2020-11-19 | Pharmaceutical composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011300901.4A CN112138138B (en) | 2020-11-19 | 2020-11-19 | Pharmaceutical composition for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112138138A CN112138138A (en) | 2020-12-29 |
| CN112138138B true CN112138138B (en) | 2023-05-23 |
Family
ID=73887447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011300901.4A Active CN112138138B (en) | 2020-11-19 | 2020-11-19 | Pharmaceutical composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112138138B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103920135A (en) * | 2014-04-23 | 2014-07-16 | 青岛昆布生物工程有限公司 | Kelp-amino composite tablet for lowering content of uric acid and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN104645332A (en) * | 2015-03-06 | 2015-05-27 | 江苏正大清江制药有限公司 | Pharmaceutical composition for relieving and preventing arthritis |
| CN105709207A (en) * | 2016-01-29 | 2016-06-29 | 徐宝贞 | Medicine for treating gout |
| WO2017203529A1 (en) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
| CN107660795A (en) * | 2017-09-01 | 2018-02-06 | 武汉龙族药号生物医药科技有限公司 | One kind prevention gout plaster taste and preparation method thereof |
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
| CN111513325A (en) * | 2020-04-29 | 2020-08-11 | 私诺(北京)健康科技有限公司 | Food for reducing uric acid |
| CN111732675A (en) * | 2020-08-18 | 2020-10-02 | 山东华熙海御生物医药有限公司 | Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
-
2020
- 2020-11-19 CN CN202011300901.4A patent/CN112138138B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN103920135A (en) * | 2014-04-23 | 2014-07-16 | 青岛昆布生物工程有限公司 | Kelp-amino composite tablet for lowering content of uric acid and preparation method thereof |
| CN104645332A (en) * | 2015-03-06 | 2015-05-27 | 江苏正大清江制药有限公司 | Pharmaceutical composition for relieving and preventing arthritis |
| CN105709207A (en) * | 2016-01-29 | 2016-06-29 | 徐宝贞 | Medicine for treating gout |
| WO2017203529A1 (en) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
| CN107660795A (en) * | 2017-09-01 | 2018-02-06 | 武汉龙族药号生物医药科技有限公司 | One kind prevention gout plaster taste and preparation method thereof |
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
| CN111513325A (en) * | 2020-04-29 | 2020-08-11 | 私诺(北京)健康科技有限公司 | Food for reducing uric acid |
| CN111732675A (en) * | 2020-08-18 | 2020-10-02 | 山东华熙海御生物医药有限公司 | Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李楠等.11.2 生物碱.《有机化学第2版》.北京：中国农业大学出版社,2017, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112138138A (en) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2491062C2 (en) | Compositions of protectors against acute and chronic hepatic encephalopathies and method of treating acute and chronic hepatic encephalopathies | |
| CN102762097B (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| CN100441220C (en) | Composition for reducing uric acid containing dipeptide of histidine and alanine | |
| CN103142655B (en) | Composite probiotics for treating podagra and preparation method thereof | |
| US20050282772A1 (en) | New dietary supplement composition for obesity and inflammation | |
| CN112546052A (en) | Composition containing marine oligosaccharide for preventing and treating gout | |
| CN112138138B (en) | Pharmaceutical composition for treating gout and preparation method thereof | |
| EP1162937B1 (en) | Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration | |
| Eneh et al. | Effect of african yam bean (Sphenostylis stenocarpa) on serum calcium, inorganic phosphate, uric acid, and alkaline phosphatase concentration of male albino rats | |
| CN113925887A (en) | Composition for inhibiting hyperuricemia and application thereof | |
| Dai et al. | RXRα-regulated liver SAMe and GSH levels influence susceptibility to alcohol-induced hepatotoxicity | |
| DE102013008875B4 (en) | Process for enzymatic purine degradation | |
| CN111939179A (en) | Application of cobra venom or extract thereof in preparation of medicine for reducing uric acid and/or resisting gouty arthritis | |
| CN118178378A (en) | Use of 10-hydroxy-2-decenoic acid in preventing and treating hyperuricemia | |
| CN110882302B (en) | Natural composition for reducing uric acid, application thereof and xanthine oxidase inhibitor | |
| US12220395B2 (en) | Intermittent endurance capacity improving agent or blood pH elevating agent | |
| EP3086659A1 (en) | Nutritional composition for the prevention and treatment of copd and related symptoms | |
| MXPA96005979A (en) | Novedous use of gluten peptides as absorption stimulants of minerals and as preventive agents of hyperlipidemia and hypercolesterole | |
| RU2698396C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
| CN105831738A (en) | Polypeptide glucosamine chondroitin nutritional health food | |
| Ghorbani et al. | Study of α-amylase inhibitors among different bean cultivars and evaluation of their effectiveness compared with a commercial product using in vitro/in vivo experimental systems | |
| CN108379455A (en) | A kind of anti-trioxypurine composition | |
| US20060105965A1 (en) | Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations | |
| JP2020100601A (en) | Nitric oxide synthase activator | |
| RU2720134C1 (en) | Pharmaceutical composition for parenteral drop introduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |